Drug Profile
Fatty acid synthesis inhibitors - KineMed/Merck
Latest Information Update: 08 Aug 2011
Price :
$50
*
At a glance
- Originator KineMed; Merck & Co
- Class
- Mechanism of Action Fatty acid synthetase complex inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Metabolic disorders
Most Recent Events
- 08 Aug 2011 No development reported - Phase-I for Metabolic disorders in USA (unspecified route)
- 20 Nov 2006 Phase-I clinical trials in Metabolic disorders in USA (unspecified route)